DISCOVER is a global observational study of patients with type 2 diabetes mellitus.
Type 2 diabetes is widespread and its prevalence is increasing rapidly worldwide. In many countries, data on treatment patterns and clinical outcomes remain scarce or incomplete and minimal information has been captured and published on newer classes of type 2 diabetes therapies, such as DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors.
DISCOVER aims to provide data on treatment patterns and the clinical course of type 2 diabetes in real world settings in patients starting a second-line anti-diabetic therapy (as add-on therapy or when switching therapies).
DISCOVER is a global, observational, non-interventional study that will be conducted in 40 countries across six continents and will enrol 15,000 patients by the end of February 2016. Patients will be followed up for 3 years. Data will be collected during routine visits using three different sources:
●electronic medical records, when available
●electronic case report forms (eCRFs), which include additional patient clinical data provided by the investigator
●patient-reported outcomes questionnaires completed by the patients.
For more information visit the DISCOVER study website at www.discoverdiabetes.com and/or check out the PDF with study information under Publications.